|
06-02-2010, 04:30 PM
|
|||
|
|||
Amgens Bone Drug Enters Competitive U.S. Osteoporosis Market
June 2 (Bloomberg) -- Amgen Inc.s bone-strengthening injection denosumab for postmenopausal women with osteoporosis will be the first biotechnology drug likely to be prescribed by patients primary physicians not specialists.
    
|
 |
| Thread Tools | |
| Display Modes | |
|
|
Similar Threads
|
||||
| Thread | Thread Starter | Forum | Replies | Last Post |
| Reportlinker Adds Competitive Outlook on Lung Cancer Drug Development - The Missing H | cancerfr | Lung Cancer | 0 | 08-25-2010 08:17 PM |
| Reportlinker Adds Target Atlas: Competitive Insights to Anti-Angiogenic Drug R&D in O | cancerfr | Gastrointestinal Carcinoid Tumor | 0 | 08-25-2010 08:17 PM |
| Liner Grode Gains Two Major Litigation Attorneys in Competitive San Francisco Market | cancerfr | Mesothelioma | 0 | 07-21-2010 12:17 AM |
| Amgens Bone Drug Cleared by U.S. for Osteoporosis (Update1) | cancerfr | Bone Cancer | 0 | 06-02-2010 04:30 PM |
| Amgens Bone Drug Cleared by U.S. for Osteoporosis (Update2) | cancerfr | Bone Cancer | 0 | 06-02-2010 04:30 PM |
Linear Mode
